Understand the source comparison
Peptide Clinics Michigan Providers Services 2026: Regulatory vs Unregulated Comparison
The table below compares Michigan-licensed peptide clinic services against common unregulated peptide sources patients encounter online. Physician Oversight Required synchronous video consultation with MI-licensed MD/DO before every prescription None. Sold as
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares Michigan-licensed peptide clinic services against common unregulated peptide sources patients encounter online.
- Physician Oversight
- Required synchronous video consultation with MI-licensed MD/DO before every prescription
- None. Sold as 'research use only' with no medical evaluation
- None. International shipments bypass prescriber requirement
- Only licensed clinics provide medical screening for contraindications (thyroid cancer history, pancreatitis risk, renal impairment)
- Purity Verification
- Third-party HPLC + mass spec testing with published CoA for every batch; FDA inspection of 503B facility
- Self-reported purity claims with no independent verification; no regulatory manufacturing oversight
- Purity unknown; counterfeit labeling common; heavy metal contamination documented in 2025 FDA import alerts
- Unverified peptides carry endotoxin, aggregation, and sequence error risks. Clinical efficacy cannot be assumed
- Legal Status in Michigan
- Prescription-only compound under MCL 333.16109; legal possession requires valid Rx
- Illegal possession without prescription under Michigan pharmacy law; sold under research exemption loophole
- Illegal importation under FDA unapproved drug provisions; customs seizure common
- Research chemical vendors exploit regulatory gray zones. Peptides are controlled drugs when intended for human use
- Dosing Accuracy
- Compounded to exact concentration specified in prescription (e.g., 2.5mg/mL semaglutide); verified by pharmacist
- Concentration often incorrect; lyophilized powder requires user reconstitution with unknown final concentration
- Vial labeling unreliable; under-dosing or over-dosing common
- Dosing errors with GLP-1 peptides cause severe hypoglycemia or treatment failure
- Adverse Event Reporting
- Mandatory FDA MedWatch reporting for 503B facilities; prescriber liable for patient outcomes
- No adverse event tracking; no accountability for contamination or reaction
- No recourse for adverse events; no identifiable manufacturer
- Patient safety depends on traceable supply chains and accountable prescribers
- Cost (30-day supply semaglutide 2.4mg)
- $250–$400 including consultation, prescription, and shipping
- $80–$150 (raw powder, no consultation)
- $60–$120 (international shipping, 3–6 week delivery)
- Lower cost unregulated sources carry hidden expenses: wasted money on inactive product, medical costs from contamination